Korean Regulatory Post Marketing Surveillance for Somavert

Pfizer

Status

Enrolling

Conditions

Acromegaly

Treatments

Drug: Somavert

Study type

Observational

Funder types

Industry

Identifiers

NCT05131100

NCT05131100 (Registry Identifier)

A6291047

Details and patient eligibility

About

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible.

Exclusion criteria

Patients who are contraindicated for Somavert